Hormone receptor‐positive, HER2‐negative (HR+/HER2−) tumours largely rely on oestrogen receptor (ER) signalling and downstream cyclin D1 (CCND1) to drive cell cycle progression through the G1/S checkpoint.2 This evidence concerns the gene CCND1 and neoplasm.